ReviewOpen forum infectious diseases2024
Immunogenicity of Current and Next-Generation Pneumococcal Conjugate Vaccines in Children: Current Challenges and Upcoming Opportunities.
Review in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy, immunogenicity, and safety of pneumococcal conjugate vaccine in children: a systematic review and meta-analysis.Frontiers in pediatrics · 2025Pooled it
- Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial.Nature medicine · 2026Trial
- Article
- Development and Validation of a Functional Antibody Assay for Evaluating Protein-Based Pneumococcal Vaccines.Vaccines · 2026Article
- Non-Vaccine Serotype Replacement and Subdominant Persistence of Vaccine Types in Nepalese Infants Following PCV10 Introduction.Vaccines · 2026Article
- Integrated analysis of humoral and T-cell responses to pneumococcal vaccination in allogeneic hematopoietic stem cell transplant recipients.Frontiers in medicine · 2026Article
- Article
- A narrative review on the effectiveness of PPSV23 vaccination in adults in China.Human vaccines & immunotherapeutics · 2025Review
- Erratum: Pneumococcal Vaccination of Adults in Italy: What Strategies?Journal of preventive medicine and hygiene · 2025Article
- Review
- Burden of Pneumococcal Disease and Adult Vaccination Landscape: An Overview with Data and Policy Insights from Türkiye.Infectious diseases & clinical microbiology · 2025Review
- Evaluation of Cholera Toxin B Subunit as a Novel Carrier Protein for Polysaccharide Conjugate Vaccines.Vaccines · 2025Article
- Recommendations on PCV20 vaccine in adults and at-risk populations.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Effectiveness of a Single Dose of Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Children: A Systematic Literature Review.Infectious diseases and therapy · 2025Review
- Pneumococcal Vaccination of Adults in Italy: What Strategies?Journal of preventive medicine and hygiene · 2025Article
- Review
- Article
- PCV13-Serotype Breakthrough Pneumococcal Disease in Infants Receiving High-Valency Conjugate Vaccines: Population-Level Modeling in France.Infectious diseases and therapy · 2025Article
- A new approach to define the optimal immunization strategy against pneumococcal disease: the example of Canada.Epidemiology and infection · 2025Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global use of pneumococcal conjugate vaccines (PCVs) with increasingly broader serotype coverage has helped to reduce the burden of pneumococcal disease in children and adults. In clinical studies comparing PCVs, higher-valency PCVs have met noninferiority criteria (based on immunoglobulin G geometric mean concentrations and response rates) for most shared serotypes. A numeric trend of declining immunogenicity against shared serotypes with higher-valency PCVs has also been observed; however, the clinical relevance is uncertain, warranting additional research to evaluate the effectiveness of new vaccines. Novel conjugation processes, carriers, adjuvants, and vaccine platforms are approaches that could help maintain or improve immunogenicity and subsequent vaccine effectiveness while achieving broader protection with increasing valency in pneumococcal vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.